EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 366 filers reported holding EXELIXIS INC in Q1 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $262,562 | -17.5% | 11,685 | -12.9% | 0.01% | -22.2% |
| Q1 2024 | $318,267 | -1.1% | 13,412 | 0.0% | 0.01% | -10.0% |
| Q4 2023 | $321,754 | -3.4% | 13,412 | -12.0% | 0.01% | -16.7% |
| Q3 2023 | $333,103 | +9.1% | 15,245 | -4.6% | 0.01% | +9.1% |
| Q2 2023 | $305,320 | -5.8% | 15,977 | -4.3% | 0.01% | -15.4% |
| Q1 2023 | $324,089 | +21.0% | 16,697 | 0.0% | 0.01% | -53.6% |
| Q4 2022 | $267,820 | +2.2% | 16,697 | 0.0% | 0.03% | +133.3% |
| Q3 2022 | $262,000 | -24.7% | 16,697 | 0.0% | 0.01% | -25.0% |
| Q2 2022 | $348,000 | -8.2% | 16,697 | 0.0% | 0.02% | +14.3% |
| Q1 2022 | $379,000 | +24.3% | 16,697 | 0.0% | 0.01% | +27.3% |
| Q4 2021 | $305,000 | -18.4% | 16,697 | -5.7% | 0.01% | -26.7% |
| Q3 2021 | $374,000 | +15.8% | 17,704 | 0.0% | 0.02% | +25.0% |
| Q2 2021 | $323,000 | -19.2% | 17,704 | 0.0% | 0.01% | -14.3% |
| Q1 2021 | $400,000 | +12.7% | 17,704 | 0.0% | 0.01% | -12.5% |
| Q4 2020 | $355,000 | -18.0% | 17,704 | 0.0% | 0.02% | -11.1% |
| Q3 2020 | $433,000 | +3.1% | 17,704 | 0.0% | 0.02% | -21.7% |
| Q2 2020 | $420,000 | +26.5% | 17,704 | -8.3% | 0.02% | -4.2% |
| Q1 2020 | $332,000 | -6.2% | 19,304 | -4.0% | 0.02% | +20.0% |
| Q4 2019 | $354,000 | -0.6% | 20,107 | 0.0% | 0.02% | -4.8% |
| Q3 2019 | $356,000 | +33.3% | 20,107 | +60.9% | 0.02% | +40.0% |
| Q2 2019 | $267,000 | -97.9% | 12,500 | +4094.6% | 0.02% | -69.4% |
| Q1 2019 | $12,500,000 | +3048.6% | 298 | -98.5% | 0.05% | +81.5% |
| Q4 2018 | $397,000 | +10.9% | 20,200 | 0.0% | 0.03% | +35.0% |
| Q3 2018 | $358,000 | +65.7% | 20,200 | -86.5% | 0.02% | -20.0% |
| Q4 2014 | $216,000 | +41.2% | 150,000 | +50.0% | 0.02% | +19.0% |
| Q3 2014 | $153,000 | -54.9% | 100,000 | 0.0% | 0.02% | -55.3% |
| Q2 2014 | $339,000 | -4.2% | 100,000 | 0.0% | 0.05% | -9.6% |
| Q1 2014 | $354,000 | -71.1% | 100,000 | -50.0% | 0.05% | -71.9% |
| Q4 2013 | $1,226,000 | – | 200,000 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
| GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
| Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
| CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
| EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
| CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
| Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
| FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
| Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |